Clinical Trial Update: Safety and Tolerability Study of AZD2171 in Combination With AZD0530 in Patients With Advanced Solid Tumours [Phase 1]

View source ↗

Summary

Phase 1 safety and tolerability study of cediranib (AZD2171) in combination with saracatinib (AZD0530) in patients with advanced solid tumors has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• AZD0530 (saracatinib)
• AZD2171 (cediranib)

Snippet

Sponsor: AstraZeneca | Conditions: Neoplasms | Phase 1 | Status: COMPLETED